Keep up to date with the latest information from the Coral Sea Clinical Research Institute.
Media resources about the CSCRI trial
A WORLD-FIRST coeliac disease vaccine is being tested which aims to end the need for gluten-free diets.
ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, initiated enrollment in Australia and New Zealand for its Phase 2 RESET CeD study assessing the safety, tolerability and efficacy of its lead therapeutic candidate, Nexvax2®, in patients with celiac disease who carry the immune recognition genes for HLA-DQ2.5.
View more articles here.
For media enquiries, please contact Tonia Wilson, Commercial Manager.